Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 8;18(24):12936.
doi: 10.3390/ijerph182412936.

Drug-Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications

Giulio Di Mizio  1 , Gianmarco Marcianò  2 , Caterina Palleria  2 , Lucia Muraca  2   3 , Vincenzo Rania  2 , Roberta Roberti  2 , Giuseppe Spaziano  4 , Amalia Piscopo  1 , Valeria Ciconte  1   2 , Nunzio Di Nunno  5 , Massimiliano Esposito  6 , Pasquale Viola  7 , Davide Pisani  7 , Giovambattista De Sarro  2   8 , Milena Raffi  9 , Alessandro Piras  9 , Giuseppe Chiarella  7 , Luca Gallelli  2   8   10
Affiliations
Review

Drug-Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications

Giulio Di Mizio et al. Int J Environ Res Public Health. .

Abstract

Peripheral vestibular disease can be treated with several approaches (e.g., maneuvers, surgery, or medical approach). Comorbidity is common in elderly patients, so polytherapy is used, but it can generate the development of drug-drug interactions (DDIs) that play a role in both adverse drug reactions and reduced adherence. For this reason, they need a complex kind of approach, considering all their individual characteristics. Physicians must be able to prescribe and deprescribe drugs based on a solid knowledge of pharmacokinetics, pharmacodynamics, and clinical indications. Moreover, full information is required to reach a real therapeutic alliance, to improve the safety of care and reduce possible malpractice claims related to drug-drug interactions. In this review, using PubMed, Embase, and Cochrane library, we searched articles published until 30 August 2021, and described both pharmacokinetic and pharmacodynamic DDIs in patients with vestibular disorders, focusing the interest on their clinical implications and on risk management strategies.

Keywords: clinical practice; clinical risk management; drug interactions; elderly; medico legal aspects; polytherapy; safety of care; vertigo; vestibular disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Yoo H., Mihaila D.M. Neuroanatomy, Vestibular Pathways. [(accessed on 25 August 2021)];2020 StatPearls . Available online: https://www.ncbi.nlm.nih.gov/books/NBK557380/
    1. Honrubia V., House M. Mechanism of posterior semicircular canal stimulation in patients with benign paroxysmal positional vertigo. Acta Otolaryngol. 2001;121:234–240. doi: 10.1111/j.1749-6632.2001.tb03769.x. - DOI - PubMed
    1. Imai T., Takeda N., Ikezono T., Shigeno K., Asai M., Watanabe Y., Suzuki M., Committee for Standards in Diagnosis of Japan Society for Equilibrium Research Classification, diagnostic criteria and management of benign paroxysmal positional vertigo. Auris Nasus Larynx. 2017;44:1–6. doi: 10.1016/j.anl.2016.03.013. - DOI - PubMed
    1. Plescia F., Salvago P., Dispenza F., Messina G., Cannizzaro E., Martines F. Efficacy and Pharmacological Appropriateness of Cinnarizine and Dimenhydrinate in the Treatment of Vertigo and Related Symptoms. Int. J. Environ. Res. Public Health. 2021;18:4787. doi: 10.3390/ijerph18094787. - DOI - PMC - PubMed
    1. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab. Rev. 2009;41:67–76. doi: 10.1080/03602530902722679. - DOI - PubMed

Substances